Back

CaMKII as a therapeutic target in catecholaminergic polymorphic ventricular tachycardia type 1

23 April 2021 (16:00 - 22:20)
Organised by:
Congress Presentation Part of: Oral abstract session - WGCCE Arrhythmias EHRA Premium Access EHRA 2021

About the speaker

Photo
Associate Professor Mani Sadredini

University of Oslo, Oslo (Norway)

8 More presentations in this session

Presentation thumbnail
Desmosomal vulnerability renders left atria more susceptible to detrimental effects of androgenic anabolic steroids
Ms L. Sommerfeld (Hamburg, DE)
Abstract Slides Video
Presentation thumbnail
The SCN5A point mutation M1875T, associated with familial atrial fibrillation, causes a gain-of-function effect of the cardiac Nav1.5 channel in atrial cardiomyocytes
Doctor M. O'Reilly (Amsterdam, NL)
Abstract Slides Video
Presentation thumbnail
OPN5 a new optogenetic receptor to study Gq signalling in the heart with light
Mr A. Wagdi Mohamed (Goettingen, DE)
Abstract Slides Video
Presentation thumbnail
Clinical, genetic and functional analysis of R562S-Kv7.1 mutation associated with long QT syndrome type 1
Doctor O. Svecova (Brno, CZ)
Abstract Slides Video
Presentation thumbnail
When multiple caveolins make the difference: Cav1 partly compensates Cav3 alterations and rescues ion channels expression.
Doctor P. Benzoni (Milan, IT)
Abstract Slides Video

Access the full session

Session thumbnail
Oral abstract session - WGCCE

The Event

Event poster

EHRA 2021

23 April 2021 16:00 CET
You may be interested in
thumbnail
Congress Session
Risk stratification
thumbnail
Congress Session
Malignant arrhythmias
thumbnail
Congress Session
Novel arrhythmia treatments

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources